Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 46,438,000	$ 42,167,000
Investment in Eton Pharmaceuticals	5,193,000	8,503,000
Accounts receivable, net	6,755,000	4,470,000
Inventories	5,132,000	4,217,000
Prepaid expenses and other current assets	1,185,000	1,305,000
Total current assets	64,703,000	60,662,000
Property, plant and equipment, net	2,792,000	3,141,000
Capitalized software development costs, net	1,758,000	1,313,000
Operating lease right-of-use assets	7,860,000	5,935,000
Intangible assets, net	15,016,000	15,813,000
Investment in Melt Pharmaceuticals	5,601,000	11,133,000
Goodwill	332,000	332,000
TOTAL ASSETS	98,062,000	98,329,000
Current liabilities
Accounts payable and accrued expenses	9,201,000	6,337,000
Accrued payroll and related liabilities	3,005,000	3,089,000
Deferred revenue and customer deposits	83,000	16,000
Current portion of operating lease obligations	633,000	272,000
Current portion of finance lease obligations		8,000
Total current liabilities	12,922,000	9,722,000
Operating lease obligations, net of current portion	7,704,000	6,012,000
Finance lease obligations, net of current portion		10,000
Loans payable, net of unamortized debt discount	72,042,000	71,654,000
TOTAL LIABILITIES	92,668,000	87,398,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000  shares authorized, 27,069,978 and 26,902,763 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	27,000	27,000
Additional paid-in capital	109,806,000	106,666,000
Accumulated deficit	(104,084,000)	(95,407,000)
TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY	5,749,000	11,286,000
Noncontrolling interests	(355,000)	(355,000)
TOTAL STOCKHOLDERS’ EQUITY	5,394,000	10,931,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 98,062,000	$ 98,329,000